A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours

Synthesis of deuterium-enriched sorafenib derivatives and evaluation of their biological activities

(2018) Lili Zhong et al.   MOLECULAR DIVERSITY

Effect of N -methyl deuteration on pharmacokinetics and pharmacodynamics of enzalutamide

(2017) Xuehai Pang et al.   JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS

Cancer statistics in China, 2015

(2016) Wanqing Chen et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database

(2016) Neehar D. Parikh et al.   HEPATOLOGY

Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma

(2016) Henry W. C. Leung et al.   Radiation Oncology

Effect of N-methyl deuteration on metabolism and pharmacokinetics of enzalutamide

(2016) Jinfang Jiang et al.   Drug Design Development and Therapy

Heavy drugs draw heavy interest from pharma backers

(2013) Alla Katsnelson   NATURE MEDICINE

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

Application of Stable Isotope-Labeled Compounds in Metabolism and in Metabolism-Mediated Toxicity Studies

(2008) Abdul E. Mutlib   CHEMICAL RESEARCH IN TOXICOLOGY

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE